Skip to main content

View Diary: Cancer patients on Medicare denied care at clinics because of sequester (42 comments)

Comment Preferences

  •  I'm not so sure this passes the sniff test. (0+ / 0-)

    Maybe I'm too cynical, or I have no clue as to the economics of these clinics, but really: a 2% cut is the difference between break even/profitable and not profitable.  But only on the most expensive 1/3 drugs?  

    Republicans: if they only had a heart.

    by leu2500 on Thu Apr 04, 2013 at 10:40:20 AM PDT

    •  33 % 0f their share (1+ / 0-)
      Recommended by:
      Pinto Pony

      since drug company 94% share remains the same

      fact does not require fiction for balance (proudly a DFH)

      by mollyd on Thu Apr 04, 2013 at 11:27:28 AM PDT

      [ Parent ]

    •  I had to read it a couple times to get it (7+ / 0-)

      The clinic purchases the drug and administers it.  As an example, the drug costs $10,000.  They receive 6% payment on top of the drug cost for adminstrative fees.  So, lets say they were being paid $10,600 for the drug plus admin.

      Now that is being cut by 2%.  The whole payment.  Now they're only being paid $10,388.  They still have to pay the pharmaceutics the full cost of the drug, of $10,388.  So their $600 admin fee just got slashed by $212.   A percentage of 35% which is HUGE considering they're only supposed to be hit with a 2% reduction.  

      If the drug cost is small, the hit is negligible.  If the drug cost is large, it's unsustainable.  

      Get it?

      How does one achieve nirvana? Lower your expectations. Problem solved. Crisis averted.

      by darlalalala on Thu Apr 04, 2013 at 11:43:06 AM PDT

      [ Parent ]

      •  Correction: (0+ / 0-)

        I said full cost payment of drug was $10,388 when I obviously meant $10,000.  Darn it!

        How does one achieve nirvana? Lower your expectations. Problem solved. Crisis averted.

        by darlalalala on Thu Apr 04, 2013 at 11:47:43 AM PDT

        [ Parent ]

        •  i once worked for a company (0+ / 0-)

          with an autoimmune drug that would have retailed for 20k per dose (one dose per year). So it does add up.

          Though one wonders if drug pricing will adjust if this isn't changed.

Subscribe or Donate to support Daily Kos.

  • Recommended (146)
  • Community (70)
  • Memorial Day (29)
  • Elections (27)
  • Environment (26)
  • Culture (26)
  • Civil Rights (26)
  • Media (25)
  • Law (24)
  • Science (24)
  • Trans-Pacific Partnership (23)
  • Labor (22)
  • Rescued (20)
  • Josh Duggar (20)
  • Economy (20)
  • Republicans (18)
  • Marriage Equality (18)
  • Ireland (17)
  • Education (17)
  • Climate Change (17)
  • Click here for the mobile view of the site